The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC) has joined the Big Ten Cancer Research Consortium. The Big Ten Cancer Research Consortium was created in 2013 to transform the conduct of cancer research through collaborative, hypothesis-driven, highly translational oncology trials that leverage the scientific and clinical expertise of the Big Ten Academic Alliance universities.
Located in Baltimore, UMGCCC offers innovative approaches to diagnosing and treating all types of cancer, conducts research to bring the latest advances in cancer treatment directly to patients in Maryland and beyond, and provides cancer screening and patient education services. It is among the 51 National Cancer Institute–designated comprehensive cancer centers in the nation.
More than 200 physicians and scientists work together at the cancer center, a joint entity of the University of Maryland Medical Center and the University of Maryland School of Medicine. More than 300 researchers are currently active in Big Ten Cancer Research Consortium Clinical Trial Working Groups, where researchers present their study concepts, receive valuable scientific feedback, and identify participating institutions to open their studies. To date, the consortium has launched 25 clinical trials and enrolled more than 500 patient volunteers.
Members of the Big Ten Cancer Research Consortium